Beyond Air, Inc. (XAIR) - Q3 2024 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2024. Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing the LungFit® platform, which generates nitric oxide (NO) from ambient air. The company's primary commercial product, LungFit® PH, received FDA approval in June 2022 and CE mark approval in November 2024. The company operates two segments: Beyond Air (medical devices) and Beyond Cancer (oncology affiliate, 80% owned).
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $1.1 million | $0.4 million | $2.6 million | $0.7 million |
| Net Loss (Total) | $(13.3) million | $(17.3) million | $(40.4) million | $(49.7) million |
| Net Loss (Attributable to Beyond Air) | $(13.0) million | $(16.2) million | $(38.6) million | $(46.5) million |
| Loss Per Share (Basic/Diluted) | $(0.15) | $(0.50) | $(0.64) | $(1.46) |
| Cash & Cash Equivalents | $4.6 million | $11.4 million | $4.6 million | $11.4 million |
| Marketable Securities | $6.3 million | $23.1 million | $6.3 million | $23.1 million |
| Total Liquidity (Cash + Securities) | $10.9 million | $34.5 million | $10.9 million | $34.5 million |
| Long-Term Debt (Net) | $0 | $14.7 million | $0 | $14.7 million |
| Related Party Long-Term Liability | $8.7 million | $0 | $8.7 million | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 174% quarter-over-quarter and 271% year-over-year (YTD), driven by expanded hospital contracts for LungFit® PH.
- Debt Restructuring: The company extinguished its $17.5 million senior secured term loan with Avenue Capital in October 2024 for a one-time payment of $17.85 million, resulting in a $1.9 million loss on extinguishment of debt in Q3. This eliminated future interest payments of $12.0 million.
- New Financing: In November 2024, the company finalized a new $11.5 million secured loan with related parties (including the CEO and a director) at 15% interest, payable in-kind through July 2026, plus an 8% royalty on net sales.
- Capital Raise: In September 2024, the company completed a private placement (Securities Purchase Agreement II) raising gross proceeds of $20.6 million ($18.9 million net) via common stock and pre-funded warrants.
- Expense Reduction: Operating expenses decreased significantly due to a capital conservation strategy, including a 30% reduction in staffing levels and the suspension of the VCAP clinical study pending funding.
Outlook, Risks, and Management Commentary
- Liquidity Concerns: Management acknowledges that current cash levels ($10.9 million) and accumulated losses ($278.3 million) raise substantial doubt about the company's ability to meet obligations without additional financing or revenue growth. Management believes this doubt is alleviated by recent cost-cutting measures and new revenue agreements.
- Commercial Strategy: The company signed agreements with TrillaMed, Healthcare Links, and Business Asia Consultants to accelerate access to DoD/VA hospitals and global markets. The company expects to enter the final phase of its U.S. commercial launch in 2025.
- Regulatory Milestones: Received CE mark approval in November 2024 for LungFit® PH, expanding indications to include peri- and post-operative pulmonary hypertension in adults and children.
- Stock Listing Risk: The company received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. It has been granted an additional 180-day compliance period (until August 4, 2025) to regain compliance, potentially via a reverse stock split.
- Equity Repricing: In November 2024, the company repriced outstanding stock options to $0.54 per share, recognizing $1.4 million in stock-based compensation expense.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $10.9 million liquidity position against the new $11.5 million related-party loan terms and ongoing burn rate.
- Nasdaq Compliance: Monitor the company's ability to meet the $1.00 minimum bid price requirement by August 4, 2025, to avoid delisting.
- Revenue Recognition: Confirm the sustainability of revenue growth given the high cost of revenue (gross loss of $0.2M in Q3) driven by device upgrades and depreciation.
- Related Party Transactions: Review the terms of the new $11.5 million loan involving the CEO and director, specifically the 15% PIK interest and 8% royalty obligations.
- Clinical Pipeline: Assess the status of the paused VCAP study and the timeline for the Phase 1b trial for Beyond Cancer's UNO therapy.